The Covid vaccine financial victors and casualties, from Novavax to Pfizer

The world has been grappling with the effects of the Covid-19 pandemic for four years now. This global health crisis has resulted in the loss of millions of lives and brought the world to a standstill. Despite this, the development of effective vaccines has been a significant milestone in the fight against the virus.

Pfizer, BioNTech, and Moderna are some of the companies that have successfully developed vaccines against Covid-19. These vaccines have generated massive revenues, with total sales surpassing $80 billion and hundreds of millions of doses administered worldwide. However, despite their financial success, investors have not been as impressed with these pharmaceutical companies’ stock performance.

Pfizer and BioNTech’s stock prices have fallen by 32% over the past five years, despite their enormous sales of their vaccine. In contrast, AstraZeneca’s share price has increased by 64% since it failed to book sales from its vaccine since last April. Even Merck, whose vaccine efforts failed twice, has seen a 56% increase in its stock price.

It’s surprising to see that despite the financial success of these vaccines, investors seem to be focusing on other factors when evaluating the performance of these pharmaceutical companies in relation to their Covid-19 vaccine sales.

By Riley Johnson

As a content writer at, I dive into the depths of information to craft compelling stories that captivate and inform readers. With a keen eye for detail and a passion for storytelling, I strive to create engaging content that resonates with our audience. Whether it's breaking news, in-depth features, or thought-provoking opinion pieces, I am dedicated to delivering high-quality, informative content that keeps readers coming back for more. My goal is to bring a fresh perspective to every article I write and to make a meaningful impact through the power of words.

Leave a Reply